Antigenic profiles of disseminated breast tumour cells and microenvironmental in bone marrow

European Journal of Surgical Oncology

Volumn 29, Issue 2, 2003, Pages 121-126

  Zhang, J ^a   Shen, Kun Wei ^a   Liu, G ^a   Zhou, J ^a   Shen, Q ^a   Shen, Z Z ^a   Shao, Z M ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bone marrow; Breast cancer; Disseminated tumour cells; Phenotype

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIGEN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; TUMOR ANTIGEN; UROKINASE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AXILLARY LYMPH NODE; BLOOD ANALYSIS; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; BREAST SURGERY; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEMORY CELL; MICROENVIRONMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR CELL; TUMOR VOLUME;

EID: 0037348473     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1334     Document Type: Article

References (25)

1. Gebauer G, Fehm T, Merkle E et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 3669-74.
2. Pantel K, Schlimok G, Angstwurm M et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumour cells in bone marrow. J Hematother 1994; 3: 165-73.
3. Ree AH, Engebraaten O, Hovig E et al. Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: gene expression profiles in bone marrow target cells. Int J Cancer 2002; 97: 28-33.
4. Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev 2000; 26: 53-65.
5. Solomayer EF, Diel IJ, Meyberg GC et al. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Breast Cancer Res Treat 1998; 49: 145-54.
6. Solomayer EF, Diel IJ, Wallwiener D et al. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer 1997; 76: 812-8.
7. Braun S, Hepp F, Sommer HL et al. Tumour-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 1999; 84: 1-5.
8. Pantel K, Schlimok G, Braun S et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85(17): 1419-24.
9. Passlick B, Sienel W, Seen-Hibler R et al. The 17-1A antigen is expressed on primary, metastatic and disseminated non-small cell lung carcinoma cells. Int J Cancer 2000; 87: 548-52.
10. Putz E, Witter K, Offner S et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumours: establishment of working models for human micrometastasis. Cancer Res 1999; 59: 241-8.
11. Feuerer M, Rocha M, Bai L et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001; 92: 96-105.
12. Pedersen AN, Christensen IJ, Stephens RW et al. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 2000; 60: 6927-34.
13. Fisher JL, Field CL, Zhou H et al. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases - a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 2000; 61: 1-12.
14. Hosch SB, Braun S, Pantel K. Characterization of disseminated tumour cells. Semin Surg Oncol 2001; 20: 265-71.
15. Braun S, Rosenberg R, Thorban S et al. Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer. Semin Surg Oncol 2001; 20: 334-46.
16. Lacroix J, Doeberitz MK. Technical aspects of minimal residual disease detection in carcinoma patients. Semin Surg Oncol 2001; 20: 252-64.
17. Sloane JP, Ormerod MG, Neville AM. Potential pathological application of immunocytochemical methods to the detection of micrometastasis. Cancer Res 1980; 40: 3079-82.
18. Mansi JL, Gogas H, Bliss JM et al. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999; 17: 197-202.
19. Diel IJ. Bone marrow staging for breast cancer: is it better than axillary node dissection? Semin Oncol 2001; 28: 236-44.
20. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-33.
21. Jiang M, Shao ZM, Wu J et al. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997; 74: 529-34.
22. Muraro PA, Pette M, Bielekova B et al. Human autoreactive CD4+ T cells from naive CD45RA+ and memory CD45RO+ subsets differ with respect to epitope specificity and functional antigen avidity. J Immunol 2000; 164: 5474-81.
23. Janicke F, Pache L, Schmitt M et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-30.
24. Duffy MJ, Reilly D, McDermott E et al. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994; 74: 2276-80.
25. Xiao J, Zhang G, Xia W. Expression and significance of urokinase-type plasminogen activator in breast cancer. Zhonghua Zhong Liu Za Zhi 1999; 21: 196-8.